Asset
LGD-6972
Ligand Pharmaceuticals Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02672839 | phase1 | completed | 2016-02-01 | 2016-05-01 | Ligand Pharmaceuticals | A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation |
| NCT02851849 | phase2 | completed | 2016-09-01 | 2017-06-01 | Ligand Pharmaceuticals | A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus |
| NCT02250222 | phase1 | completed | 2014-10-01 | 2015-05-01 | Ligand Pharmaceuticals | Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus |
| NCT01919684 | phase1 | completed | 2013-11-01 | 2014-02-01 | Ligand Pharmaceuticals | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus |
FDA applications (0)
This company has no applications containing this asset.